Belinostat

U. S. Food and Drug Administration granted accelerated approval to belinostat (BELEODAQ, Spectrum Pharmaceuticals, Inc.) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). July 3, 2014.  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery